ODTC — Odonate Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Brief: Positive Results Of Contessa, A Phase 3 Study Of Tesetaxel In Patients With Metastatic Breast Cancer, Presented At The 2020 San Antonio Breast Cancer Symposium (Sabcs)
Brief: Odonate Therapeutics Initiates Cohort 3 Of Contessa Trio for Tesetaxel Monotherapy In Metastatic Breast Cancer Patients
Brief: Odonate Therapeutics Inc Files For Stock Shelf Of Up To $150 Million – SEC Filing
Brief: Odonate Therapeutics Announces Financial Results For The Three And Nine Months Ended September 30, 2020
Brief: Odonate Therapeutics Announces Pricing Of Public Offering Of 5.61 Mln Common Shares At $14.25 Per Share
Brief: Odonate Therapeutics Says Co Is Offering $80 Million Of Shares Of Common Stock
Odonate Therapeutics falls on proposed stock offering
Brief: Odonate Therapeutics Announces Public Offering of Shares of Common Stock
Odonate: Breast cancer drug trial results fail to impress Street - Jefferies
Brief: Odonate Therapeutics Announces Positive Results From Phase 3 Study Of Tesetaxel To Treat Metastatic Breast Cancer
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Brief: Odonate Therapeutics Posts Quarterly Loss Per Share $1.09
Brief: Odonate Therapeutics Reports Quarterly Loss Per Share $0.99
FDA's guidance on clinical trials good, but issues will arise- analyst
Brief: Odonate Therapeutics Reports Q4 Loss Per Share Of $0.91
Brief: Odonate Therapeutics Q3 Loss Per Share $0.88
Brief: Odonate Therapeutics Announces Completion Of Enrollment In CONTESSA
Brief: Odonate Therapeutics May Sell Up To $200 Mln Of Common Stock
Brief: Odonate Therapeutics Says Qtrly Loss Per Share of $1.15